期刊文献+

系列测定血清降钙素原在指导肺部感染疗效评估中的作用 被引量:10

The role of serial measurements of serum procalcitonin in efficacy evaluation in patients with pneumonia
下载PDF
导出
摘要 目的探讨系列监测血清降钙素原(procalcitonin,PCT)在指导肺部感染治疗效果评价中的作用。方法前瞻性单中心观察研究,我院ICU中需要机械通气的肺部感染患者在24 h内入选。分别在24、72 h,第7天和治疗结束时测定血清PCT。按《抗菌药物临床研究指导原则》评价疗效并分为有效组(n=48)与失败组(n=25),比较两组间PCT的变化规律。结果 73例患者入选,平均年龄(60.7±19.8)岁。治疗后72 h早期疗效评估时,两组PCT变化率分别为(34.1±14.6)%和(13.7±6.5)%,差异有统计学意义(P=0.009),而PCT值分别为(2.25±0.95)μg/L和(3.59±1.17)μg/L(P=0.045)。就预测疗效的单一指标而言,72 h PCT变化率的受试者工作曲线下面积(AUC)为0.811(P=0.002),优于临床肺感染评分(CPIS)(AUC=0.688)、PCT值、体温及白细胞计数(P均>0.05)。72 h的PCT变化率(下降>31.7%)联合CPIS(<6分)的AUC为0.931,灵敏度为83.8%,特异度为91.7%。结论系列监测PCT有助于指导肺部感染治疗效果评价,特别是72 hPCT变化率能早期预测疗效,联合CPIS可进一步提高其预测价值。 Objective This study aimed to determine if serial measurements of procalcitonin (PCT) could inform the efficacy evaluation in patients with pneumonia. Methods A prospective, single center, observational study was conducted in eligible patients with severe pneumonia in ICU. PCT samples were collected at baseline, 72 hours, 7 clays and end of therapy. Patients were divided into responder group (n = 48) and nonresponder group (n = 25). Results Seventy-three patients were evaluable. The mean age was 60.7 ± 19.8 years. The change of PCT within the first 72 hours (ΔPCTm %) was significantly different between the two groups (34.1% ± 14.6% vs 13.7% ± 6.5%, P=0.009). The PCT level was (2.25±0.95) μg/Land (3.59 ± 1.17) μg/L respectively (P = 0. 045). The area under the curve (AUC) of ΔPCTD3 % for predicting clinical efficacy was 0. 811 (P= 0. 002), better than Clinical Pulmonary Infection Score (CPIS) (AUC= 0. 688), PCT level, white blood cell count and body temperature (P〉0.05). Especially, the ΔPCTD3 % (cut-off 〉31. 7%) in combination with CPIS (〈6) was associated with the best performance to predict clinical efficacy with a AUC of 0. 931, sensitivity of 83.8% and specificity of 91.7%. Conclusions Serial measurements of PCT can reflect the treatment response of antimicrobial therapy. Especially, the ΔPCTD3 % plus CPIS can improve the prediction of treatment effect for pneumonia at early stage.
出处 《中国感染与化疗杂志》 CAS 北大核心 2013年第3期190-194,共5页 Chinese Journal of Infection and Chemotherapy
关键词 降钙素原 肺部感染 疗效评价 procalcitonin pulmonary infection efficacy evaluation
  • 相关文献

参考文献17

  • 1Marshall JC, Reinhart K, International Sepsis Forum. Biomarkers of sepsis[J]. Crit Care Med, 2009, 37(7):2290-2298.
  • 2Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis[J]. Clin Infect Dis, 2004, 39(2): 206-217.
  • 3石岩,刘大为.降钙素原在全身性感染诊治中的研究进展[J].中华内科杂志,2011,50(5):444-446. 被引量:93
  • 4Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalci tonin for sepsis diagnosis in critically ill patients: systematic review and metaanalysis [ J ]. Lancet Infect Dis, 2007,7 (3) :210-227.
  • 5Christ-Crain M, Muller B. Procalcitonin in bacterial infections-hype,hope more or less? [J]. Swiss Med Wkly, 2005, 135(31-32) : 451-460.
  • 6社区获得性肺炎诊断和治疗指南(草案)[J].中华结核和呼吸杂志,1999,22(4):199-201. 被引量:1037
  • 7American Thoracic Society, Infectious Disease Society of A merica. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia[J]. Am J Respir Crit Care Med, 2005, 171(4) : 388-416.
  • 8Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008[J]. Crit Care Med, 2008,36 (1) :296-327.
  • 9卫生部抗生素临床药理基地.抗菌药物临床研究指导原则.中国临床药理学杂志,1987,2:189-191.
  • 10Schuetz P,Christ-Crain M,Thomann R,et al. Effect of procaleitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infeetions: the ProHOSP randomized controlled trial [J]. JAMA, 2009, 302 ( 10 ) : 1059 1066.

二级参考文献30

  • 1Müller B,Becker KL.Procalcitonin:how a hormone became a marker and mediator of sepsis.Swiss Med Wkly,2001,131:595-602.
  • 2Becker KL,Nylén ES,White JC,et al.Clinical review 167:Procalcitonin and the calcitonin gene family of peptides in inflammation,infection,and sepsis:a journey from calcitonin back to its precursors.J Clin Endocrinol Metab,2004,89:1512-1525.
  • 3Castelli GP,Pognani C,Meisner M,et al.Procalcitonin and Creactive protein during systemic inflammatory response syndrome,sepsis and organ dysfunction.Crit Care,2004,8:R234-242.
  • 4Endo S,Aikawa N,Fujishima S,et al.Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis:a multicenter prospective study.J Infect Chemother,2008,14:244-249.
  • 5Harbarth S,Holeckova K,Froidevaux C,et al.Diagnostic value of procalcitonin,interleukin-6,and interleukin-8 in critically ill patients admitted with suspected sepsis.Am J Respir Crit Care Med,2001,164:396-402.
  • 6Simon L,Gauvin F,Amre DK,et al.Serum procalcitonin and Creactive protein levels as markers of bacterial infection:a systematic review and meta-analysis.Clin Infect Dis,2004,39:206-217.
  • 7Uzzan B,Cohen R,Nicolas P,et al.Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma:a systematic review and meta-analysis.Crit Care Med,2006,34:1996-2003.
  • 8Oberhoffer M,Stonans I,Russwurm S,et al.Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsisrelated cytokines in vitro.J Lab Clin Med,1999,134:49-55.
  • 9Gibot S,Cravoisy A,Levy B,et al.Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia.N Engl J Med,2004,350:451-458.
  • 10Tejera A,Santolaria F,Diez ML,et al.Prognosis of community acquired pneumonia (CAP):value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response.Cytokine,2007,38:117-123.

共引文献1151

同被引文献88

  • 1Campos S. Ventilator-associated pneumonia:the unresolved issues ofprevention and diagnosis [ J]. Pediatr Crit Care Med ,2012,13(1):112-114.
  • 2S6gu6la PE,Joram N,Romefort B,et al. Procalcitonin as> a marker ofbacterial infection in children undergoing cardiac surgery with car-diopulmonary bypass[ J]. Cardiol Young,2011,21 (4) :392 -399.
  • 3Su L,Meng K,Zhang X,et al. Diagnosing ventilator-associated pneu-monia in critically ill patients with sepsis[ J]. Am J Crit Care,2012,21(6):en0-ell9.
  • 4ZieliAska-Borkowska U,Skirecki T,Ziotorowicz M,et al. Procalcito-nin in early onset ventilator-associated pneumonia [ J ] . J Hosp In-fect,2012 ,81 (2) :92-97.
  • 5Abu Elkhashab AE, Swelem RS, Abd Alla AEDA, et al. Etiologicaland prognostic values of procalcitonin in hospital-acquired pneumo-nia[ J]. Egyptian Journal of Chest Diseases and Tuberculosis,2014,63(1) :201 -206.
  • 6Certain L, Schuetz P. The role of procalcitonin in respiratory infec-tions[J].Curr Infect Dis Rep,2012,14⑶:308 -316.
  • 7Campos S.Ventilator-associated pneumonia:The unresolved issuesof prevention and diagnosis[J].Pediatric Critical Care Medicine,2012,13(1):112-114.
  • 8Zielifiska-Borkowska U,Skirecki T,Zlotorowicz M,et al.Procalcitonin in early onset ventilator-associated pneumonia[J].Journal of Hospital Infection,2012,81(2):92-97.
  • 9LINDSTROM ST, WONG EK. Procalcitonin, a valuable biomarker as- sisting clinical decision-making in the management of community- acquired pneumonia[J]. Intern Med J,2014,44(d):390-397.
  • 10杨福堂,王淑云,吕培瑾,李燕,郝泽蕊,侯庆民.重症肺炎40例临床分析[J].临床肺科杂志,2009,14(5):601-602. 被引量:13

引证文献10

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部